Equities

AxoGen Inc

AxoGen Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)13.32
  • Today's Change0.22 / 1.68%
  • Shares traded82.51k
  • 1 Year change+125.76%
  • Beta1.0581
Data delayed at least 15 minutes, as of Nov 22 2024 18:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for AxoGen Inc have a median target of 17.00, with a high estimate of 20.00 and a low estimate of 16.00. The median estimate represents a 29.77% increase from the last price of 13.10.
High52.7%20.00
Med29.8%17.00
Low22.1%16.00

Earnings history & estimates in USD

On Nov 07, 2024, AxoGen Inc reported 3rd quarter 2024 earnings of 0.07 per share. This result exceeded the 0.01 consensus of the 5 analysts covering the company and exceeded last year's 3rd quarter results by 0.06.
The next earnings announcement is expected on Mar 11, 2025.
Average growth rate+20.00%
AxoGen Inc reported annual 2023 losses of -0.17 per share on Mar 05, 2024.
Average growth rate+18.78%
More ▼

Revenue history & estimates in USD

AxoGen, Inc. had 3rd quarter 2024 revenues of 48.64m. This bettered the 47.07m consensus of the 7 analysts covering the company. This was 32.68% above the prior year's 3rd quarter results.
Average growth rate+4.43%
AxoGen, Inc. had revenues for the full year 2023 of 159.01m. This was 14.74% above the prior year's results.
Average growth rate+10.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.